STOCKHOLM, Nov. 8, 2022 /PRNewswire/ --
Link to press release from November 7th: http://investors.scibase.se/en/scibase-announces-collaboration-to-detect-skin-barrier-dysfunction-in-infants
Link to CEO comment: https://players.brightcove.net/1555966121001/default_default/index.html?videoId=6315110856112
For more information around skin barrier and SciBase: https://barrier.scibase.com/
For more information, please contact:
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com . All press-releases and financial reports can be found here :
http://investors.scibase.se/en/pressreleases
The following files are available for download: